1. Home
  2. CBIO vs WTBA Comparison

CBIO vs WTBA Comparison

Compare CBIO & WTBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • WTBA
  • Stock Information
  • Founded
  • CBIO 2003
  • WTBA 1893
  • Country
  • CBIO United States
  • WTBA United States
  • Employees
  • CBIO N/A
  • WTBA N/A
  • Industry
  • CBIO
  • WTBA Major Banks
  • Sector
  • CBIO
  • WTBA Finance
  • Exchange
  • CBIO Nasdaq
  • WTBA Nasdaq
  • Market Cap
  • CBIO 308.0M
  • WTBA 332.5M
  • IPO Year
  • CBIO N/A
  • WTBA N/A
  • Fundamental
  • Price
  • CBIO $14.29
  • WTBA $19.96
  • Analyst Decision
  • CBIO Strong Buy
  • WTBA Hold
  • Analyst Count
  • CBIO 5
  • WTBA 2
  • Target Price
  • CBIO $25.60
  • WTBA $21.75
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • WTBA 33.3K
  • Earning Date
  • CBIO 07-31-2025
  • WTBA 10-23-2025
  • Dividend Yield
  • CBIO N/A
  • WTBA 5.01%
  • EPS Growth
  • CBIO N/A
  • WTBA 33.79
  • EPS
  • CBIO N/A
  • WTBA 1.70
  • Revenue
  • CBIO N/A
  • WTBA $87,098,000.00
  • Revenue This Year
  • CBIO N/A
  • WTBA $24.40
  • Revenue Next Year
  • CBIO N/A
  • WTBA $9.68
  • P/E Ratio
  • CBIO N/A
  • WTBA $11.74
  • Revenue Growth
  • CBIO N/A
  • WTBA 15.15
  • 52 Week Low
  • CBIO $10.83
  • WTBA $17.31
  • 52 Week High
  • CBIO $21.40
  • WTBA $24.85
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • WTBA 60.68
  • Support Level
  • CBIO $13.50
  • WTBA $19.72
  • Resistance Level
  • CBIO $16.00
  • WTBA $20.13
  • Average True Range (ATR)
  • CBIO 0.79
  • WTBA 0.51
  • MACD
  • CBIO 0.16
  • WTBA 0.19
  • Stochastic Oscillator
  • CBIO 39.68
  • WTBA 92.77

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About WTBA West Bancorporation

West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.

Share on Social Networks: